Vanderbilt Oncology Pharmacy

Nashville, Tennessee 37232

We've found

3 trials

at this facility

A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Nashville, TN

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Status: Enrolling, Phase I
Updated: 12/31/1969

from

Nashville, TN

Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Ab, In Relapse/ Refractory Multiple Myeloma

Status: Enrolling, Phase I
Updated: 12/31/1969

from

Nashville, TN

Use our guide to learn which trials are right for you!